Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4Recruiting 1No longer available 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 4Observational 1Expanded_access 1

Sponsor

Conditions

Breast Neoplasms 13138Neoplasms 10481Carcinoma, Non-Small-Cell Lung 6874Prostatic Neoplasms 6268Colorectal Neoplasms 5948Lung Neoplasms 5105Multiple Myeloma 3577Pancreatic Neoplasms 3563Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3508Carcinoma, Hepatocellular 3273Ovarian Neoplasms 3168Melanoma 3141Stomach Neoplasms 3057Lymphoma 2983Head and Neck Neoplasms 2604Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2313Lymphoma, Non-Hodgkin 2269Rectal Neoplasms 2192Uterine Cervical Neoplasms 2191Glioblastoma 2016Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1848Esophageal Neoplasms 1801

Interventions

tremelimumab 1durvalumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Advanced Malignancy × Clear all
NCT07123129 2026-01-30

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1 Recruiting
200 enrolled

Advanced Malignancy

NCT03875157 2023-02-27

Study of IBI318 in Participants With Advanced Malignancies

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Completed
103 enrolled

Advanced Malignancy

NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

AstraZeneca

Phase 1 Completed
26 enrolled

Advanced Malignancy

NCT04216082 2020-01-02

A Study of Anlotinib in Subjects With Advanced Malignancy

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
93 enrolled

Advanced Malignancy

NCT01945164 2014-10-21

XL999 Administered Intravenously to a Subject With Advanced Malignancies

The University of Texas Health Science Center at San Antonio

No longer available

Advanced Malignancy

NCT00978926 2010-04-09

A Study of the Pharmacodynamic Effects of Anti-Vascular Endothelial Growth Factor Therapy in Patients With Advanced Malignancies

National University Hospital, Singapore

Completed

Advanced Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡